Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Current Deferred Revenue (2019 - 2025)

Biodesix's Current Deferred Revenue history spans 7 years, with the latest figure at $961000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 41.74% year-over-year to $961000.0; the TTM value through Dec 2025 reached $961000.0, up 41.74%, while the annual FY2025 figure was $961000.0, 41.74% up from the prior year.
  • Current Deferred Revenue reached $961000.0 in Q4 2025 per BDSX's latest filing, down from $2.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.8 million in Q3 2025 to a low of $300000.0 in Q4 2023.
  • Average Current Deferred Revenue over 5 years is $1.3 million, with a median of $1.0 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: tumbled 72.37% in 2024, then surged 300.0% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.9 million in 2021, then crashed by 47.37% to $1.0 million in 2022, then tumbled by 70.0% to $300000.0 in 2023, then soared by 126.0% to $678000.0 in 2024, then soared by 41.74% to $961000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Current Deferred Revenue are $961000.0 (Q4 2025), $2.8 million (Q3 2025), and $617000.0 (Q2 2025).